Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb;47(2):240-5.
doi: 10.1016/j.jpsychires.2012.10.010. Epub 2012 Nov 10.

Cannabis withdrawal in chronic cannabis users with schizophrenia

Affiliations

Cannabis withdrawal in chronic cannabis users with schizophrenia

Douglas L Boggs et al. J Psychiatr Res. 2013 Feb.

Abstract

Background: Chronic users of cannabis often report withdrawal symptoms after abstinence from use, but little is known about cannabis withdrawal in people with schizophrenia.

Methods: Cannabis use patterns and withdrawal symptoms in adults with schizophrenia who had at least weekly cannabis use before attempting to quit without formal treatment were assessed with the Marijuana Quit Questionnaire (MJQQ), a 176-item, semi-structured questionnaire.

Results: 120 participants, predominantly African-American (62.5%) and male (76.7%), met inclusion criteria. 20.1% reported that their first regular cannabis use (median age 15 years [range 8-48]) preceded their age at first psychotic symptoms (20 [4-50] years). Twenty (16.7%) participants met lifetime criteria for cannabis abuse; 98 (81.7%) met surrogate criteria for lifetime cannabis dependence. Withdrawal symptoms were reported by 113 (94.2%) participants, with 74.2% reporting ≥4 symptoms. The most frequently reported withdrawal symptoms were craving for cannabis (59.2%), feeling anxious (52.57%), feeling bored (47.5%), feeling sad or depressed (45.8%), feeling irritable or jumpy (45.0%), feeling restless (43.3%), and trouble failing asleep (33.3%). One hundred-and-four (92.0%) participants took some action to relieve at least one of their withdrawal symptoms during their index-quit attempt, including 26 (23.0%) participants who reported resuming cannabis use.

Conclusion: Cannabis withdrawal is a clinically significant feature of cannabis use among people with schizophrenia, may serve as a negative reinforcer for relapse, and deserves greater attention in treatment and research. Clinical Trials registration NCT00679016.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors have no conflicts of interest to declare.

References

    1. Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ. The cannabis withdrawal scale development: patterns and predictors of cannabis withdrawal and distress. Drug and Alcohol Dependence. 2011;119:123–129. - PubMed
    1. Arendt M, Rosenberg R, Foldager L, Sher L, Munk-Jorgensen P. Withdrawal symptoms do not predict relapse among subjects treated for cannabis dependence. American Journal of Addictions. 2007;16:461–467. - PubMed
    1. Barnett JH, Werners U, Secher SM, Hill KE, Brazil R, Masson K, et al. Substance use in a population-based clinic sample of people with first-episode psychosis. British Journal of Psychiatry. 2007;190:515–520. - PubMed
    1. Bartels SJ, Drake RE, Wallach MA, Freeman DH. Characteristic hostility in schizophrenic outpatients. Schizophrenia Bulletin. 1991;17:163–171. - PubMed
    1. Bhuvaneswar CG, Baldessarini RJ, Harsh VL, Alpert JE. Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. CNS Drugs. 2009;23:1003–1021. - PubMed

Publication types

Associated data